Capsule endoscopy versus standard tests in influencing management of obscure digestive bleeding:: Results from a German multicenter trial

被引:79
|
作者
Neu, B
Ell, C
May, A
Schmid, E
Riemann, JF
Hagenmüller, F
Keuchel, M
Soehendra, N
Seitz, U
Meining, A
Rösch, T
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, D-81675 Munich, Germany
[2] Univ Mainz, Horst Schmidt Hosp, Wiesbaden, Germany
[3] Municipal Hosp, Ludwigshafen, Germany
[4] Altona Hosp, Hamburg, Germany
[5] Univ Hosp Eppendorf, Hamburg, Germany
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2005年 / 100卷 / 08期
关键词
D O I
10.1111/j.1572-0241.2005.41649.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Capsule endoscopy (CE) is a new modality for obscure digestive bleeding (OBD), but little is known about its influence on management and outcome. PATIENTS AND METHODS: Fifty-six patients (male/female 26/30; mean age 63 yr) with ODB, and negative upper and lower gastrointestinal (GI) endoscopy were included in this multicenter study. The diagnostic yield of CE was compared to three other tests (OT: push enteroscopy, enteroclysis, angiography), and patients were followed up for at least 6 months. Parameters were analyzed that led to major management changes such as surgical or endoscopic intervention or specific medical therapy, as well as their correlation to further bleeding. RESULTS: CE had a diagnostic yield higher than OT (68%vs 38%). Major management changes and an improvement in bleeding activity were observed in 21 and 44 patients, respectively. The number and type of positive findings on CE were associated with significant management changes (p < 0.05). The number of positive findings detected by CE as well as by OT correlated with further bleeding episodes (p < 0.05). However, clinical parameters (lowest hemoglobin (Hb) value, number of blood transfusions) were also significantly associated with outcome. Diagnoses of specific diseases (tumor, Crohn, NSAID ulcer) by CE led to a favorable outcome in 64% of cases, whereas negative CE cases were associated with no further bleeding in 80%. CONCLUSION: CE helps with management decisions and can replace other more complex and risky standard tests. Nevertheless, clinical parameters are equally important for predicting further bleeding and should also be used to decide on further management.
引用
收藏
页码:1736 / 1742
页数:7
相关论文
共 38 条
  • [31] Correction: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease—results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health
    Daniel Wolff
    Philipp Y. Herzberg
    Anne Herrmann
    Steven Z. Pavletic
    Pia Heussner
    Friederike Mumm
    Christina Höfer
    Inken Hilgendorf
    Philipp G. Hemmati
    Ernst Holler
    Hildegard Greinix
    Sandra A. Mitchell
    Bone Marrow Transplantation, 2021, 56 : 2618 - 2618
  • [32] Carotid Stent Fractures Are Not Associated With Adverse Events Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease)
    Weinberg, Ido
    Beckman, Joshua A.
    Matsumura, Jon S.
    Rosenfield, Kenneth
    Ansel, Gary M.
    Chaturvedi, Seemant
    Gray, William
    Metzger, D. Chris
    Riles, Tom
    Shu, Yu
    Wechsler, Lawrence
    Jaff, Michael R.
    CIRCULATION, 2018, 137 (01) : 49 - +
  • [33] Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health (vol 56, pg 243, 2021)
    Wolff, Daniel
    Herzberg, Philipp Y.
    Herrmann, Anne
    Pavletic, Steven Z.
    Heussner, Pia
    Mumm, Friederike
    Hofer, Christina
    Hilgendorf, Inken
    Hemmati, Philipp G.
    Holler, Ernst
    Greinix, Hildegard
    Mitchell, Sandra A.
    BONE MARROW TRANSPLANTATION, 2021, 56 (10) : 2618 - 2618
  • [34] Does the Length of the Common Channel as Part of the Total Alimentary Tract Matter? One Year Results from the Multicenter Dutch Common Channel Trial (DUCATI) Comparing Standard Versus Distal Roux-en-Y Gastric Bypass with Similar Biliopancreatic Bowel Limb Lengths
    Gadiot, Ralph P. M.
    Leeman, M.
    Biter, L. Ulas
    Dunkelgrun, Martin
    Apers, Jan A.
    Hof, Gerhard van't
    Feskens, Pierre B.
    Mannaerts, Guido H.
    OBESITY SURGERY, 2020, 30 (12) : 4732 - 4740
  • [35] Does the Length of the Common Channel as Part of the Total Alimentary Tract Matter? One Year Results from the Multicenter Dutch Common Channel Trial (DUCATI) Comparing Standard Versus Distal Roux-en-Y Gastric Bypass with Similar Biliopancreatic Bowel Limb Lengths
    Ralph P. M. Gadiot
    M. Leeman
    L. Ulas Biter
    Martin Dunkelgrun
    Jan A. Apers
    Gerhard van’t Hof
    Pierre B. Feskens
    Guido H. Mannaerts
    Obesity Surgery, 2020, 30 : 4732 - 4740
  • [36] Letter by Su et al Regarding Article, "Carotid Stent Fractures Are Not Associated With Adverse Events: Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease)"
    Su, Qiang
    Ye, Ziliang
    Li, Lang
    CIRCULATION, 2018, 137 (24) : 2674 - 2675
  • [37] Response by Weinberg et al to Letter Regarding Article, "Carotid Stent Fractures Are Not Associated With Adverse Events: Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease)"
    Weinberg, Ido
    Beckman, Joshua A.
    Shu, Yu
    Jaff, Michael R.
    CIRCULATION, 2018, 137 (24) : 2676 - 2677
  • [38] Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
    Al-Batran, Salah-Eddin
    Lorenzen, Sylvie
    Thuss-Patience, Peter C.
    Homann, Nils
    Schenk, Michael
    Lindig, Udo
    Heuer, Vera
    Kretzschmar, Albrecht
    Goekkurt, Eray
    Haag, Georg Martin
    Knorrenschild, Jorge Riera
    Bolling, Claus
    Hofheinz, Ralf-Dieter
    Angermeier, Stefan
    Ettrich, Thomas Jens
    Siebenhuener, Alexander
    Kopp, Christina
    Pauligk, Claudia
    Goetze, Thorsten Oliver
    Gaiser, Timo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)